With International Women's Day celebrated just a few days ago, there’s no better time to take a look at some of the most inspiring female entrepreneurs who have fought the odds and made a success of their ventures.
Muskan Sethi
Muskan Sethi is a professional poker player and entrepreneur from India. Shethi first made a name for herself in poker when she appeared on Shark Cage, a show where contestants take on some of the biggest names in the sport in the hopes of winning $1 million. This TV appearance supercharged her professional poker career, which has seen her become a PokerStars India Ambassador and the Responsible Gaming Ambassador for the All India Gaming Federation.
Sethi has tried her hand at more than just poker, though. She has a degree in Fashion Journalism and Brand Management from the London School of Fashion and is also a whiz on computers, having spent several years learning about them. She is also the founder of Doggydoo, which aims to connect dog lovers to help them support each other.
Wilhelmina Myeonway Cooper
Wilhelmina Myeonway Cooper started her business in 2013—something very few women in Liberia manage to do. Just starting was a huge accomplishment, but that wasn’t enough for her, and she was determined to make it a success.
She started working with local artists and bag makers to create unique products for her customers. She hit a problem, though—she didn’t have the money to open a shop in the place where her customers would be.
To overcome this, she started the Monrovia African Pop Up Shop, which lets small businesses showcase their merchandise at high-traffic areas in the country’s capital. It quickly grew from nine vendors to 50 taking part in just two years. She now has plans to expand across Africa.
Zhou Qunfei
If you’re reading this on a smartphone (chances are you probably are), then you need to thank Zhou Qunfei for her company’s contribution to its existence. She founded Lens Technology, a company that supplies some of the biggest tech giants—like Samsung, LG, and Apple—with the touchscreens that they put in their smartphones.
As you can imagine, there’s a lot of money to be made when you supply key components to most of the world’s smartphone manufacturers, particularly when you consider that there are now more than 5 billion mobile devices in existence today. Qunfei is now the richest female self-made billionaire in the world—a significant achievement after having started her working life on the shop floor of a Chinese migrant factory.
Katy Kippen
Katy Kippen started her business, Grayling Jewelry, in 2009. She continues to have an all-female team that is equally as passionate about jewelry. Kippen has been surrounded by precious metals and gemstones her entire life, having learned about them from her grandfather.
She lived in Europe and Asia for six years, which allowed her to pick up a lot of inspiration for the products she now produces.
A big unique selling point for Grayling Jewelry is that all of its products are hypo-allergenic. The idea for this came from the fact that Kippen has a nickel allergy—a common affliction that means many items of jewelry can irritate the wearer’s skin.
All her products are hand-made in the United States, which means she produces unique products while also supporting the local economy. She has seen a lot of success; her products are stocked in her own store in Portland, as well as in 10 others in the US.
While there is still a long way to go towards bringing a complete balance for women, these inspirational ladies are leading the way for many more to follow. In the last 20 years, the number of women that hold top positions in FTSE 100 companies has increased by more than 100%—however, it continues to be less than men.
Perhaps starting and growing their own businesses is the best way that they can tackle this imbalance, particularly since it is becoming easier than ever to start your own business online.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.